These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 11556834)

  • 41. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.
    Liu L; Dilworth D; Gao L; Monzon J; Summers A; Lassam N; Hogg D
    Nat Genet; 1999 Jan; 21(1):128-32. PubMed ID: 9916806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel and recurrent p14 mutations in Italian familial melanoma.
    Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
    Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
    Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
    Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
    Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
    Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.
    Soto JL; Cabrera CM; Serrano S; López-Nevot MA
    BMC Cancer; 2005 Apr; 5():36. PubMed ID: 15819981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. eMelanoBase: an online locus-specific variant database for familial melanoma.
    Fung DC; Holland EA; Becker TM; Hayward NK; Bressac-de Paillerets B; Mann GJ;
    Hum Mutat; 2003 Jan; 21(1):2-7. PubMed ID: 12497626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
    Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
    Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
    Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
    Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
    Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
    Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The genetics of cutaneous melanoma.
    Pollock PM; Trent JM
    Clin Lab Med; 2000 Dec; 20(4):667-90. PubMed ID: 11221509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
    Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
    Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
    Reymond A; Brent R
    Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families.
    Tucker MA; Fraser MC; Goldstein AM; Struewing JP; King MA; Crawford JT; Chiazze EA; Zametkin DP; Fontaine LS; Clark WH
    Cancer; 2002 Jun; 94(12):3192-209. PubMed ID: 12115352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genes involved in melanoma: an overview of INK4a and other loci.
    Castellano M; Parmiani G
    Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
    Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
    Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
    Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
    Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.